- Home
- HOLO vs SPRO Comparison
HOLO vs SPRO Comparison
Compare HOLO & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- SPRO
- Stock Information
- Founded
- HOLO 2018
- SPRO 2013
- Country
- HOLO China
- SPRO United States
- Employees
- HOLO N/A
- SPRO N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- HOLO Technology
- SPRO Health Care
- Exchange
- HOLO Nasdaq
- SPRO Nasdaq
- Market Cap
- HOLO 50.1M
- SPRO 45.7M
- IPO Year
- HOLO N/A
- SPRO 2017
- Fundamental
- Price
- HOLO $0.94
- SPRO $0.75
- Analyst Decision
- HOLO
- SPRO Buy
- Analyst Count
- HOLO 0
- SPRO 4
- Target Price
- HOLO N/A
- SPRO $5.00
- AVG Volume (30 Days)
- HOLO 32.8M
- SPRO 97.8K
- Earning Date
- HOLO 01-01-0001
- SPRO 03-21-2025
- Dividend Yield
- HOLO N/A
- SPRO N/A
- EPS Growth
- HOLO N/A
- SPRO N/A
- EPS
- HOLO N/A
- SPRO 0.06
- Revenue
- HOLO $32,242,196.00
- SPRO $106,455,000.00
- Revenue This Year
- HOLO N/A
- SPRO N/A
- Revenue Next Year
- HOLO N/A
- SPRO N/A
- P/E Ratio
- HOLO N/A
- SPRO $11.65
- Revenue Growth
- HOLO 326.95
- SPRO 37.01
- 52 Week Low
- HOLO $0.92
- SPRO $0.73
- 52 Week High
- HOLO $171.60
- SPRO $1.89
- Technical
- Relative Strength Index (RSI)
- HOLO 40.80
- SPRO 35.73
- Support Level
- HOLO $0.92
- SPRO $0.73
- Resistance Level
- HOLO $1.15
- SPRO $0.80
- Average True Range (ATR)
- HOLO 0.17
- SPRO 0.03
- MACD
- HOLO 0.02
- SPRO 0.00
- Stochastic Oscillator
- HOLO 9.18
- SPRO 16.91
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.